Literature DB >> 3315512

Reproducibility of beta-cell function estimates in non-insulin-dependent diabetes mellitus.

H J Gjessing, E M Damsgaard, L E Matzen, A Frøland, O K Faber.   

Abstract

We evaluated the reproducibility of different estimates of endogenous insulin secretion in 30 patients with non-insulin-dependent diabetes mellitus (NIDDM). Fasting blood glucose concentration was similar on the 2 days of study. The coefficients of variation of fasting plasma C-peptide, plasma C-peptide 6 min after the injection of 1 mg i.v. glucagon, and the increment in plasma C-peptide after glucagon were 16.0, 14.8 and 24.1%, respectively. The coefficients of variation of the corresponding plasma insulin values were 19.2, 24.8, and 34.8%, respectively. The coefficient of variation of 24-h urinary C-peptide excretion was 22.1%. Because fasting plasma C-peptide correlated closely with plasma C-peptide 6 min after glucagon (test 1: r = .70, P less than .01; test 2: r = .76, P less than .01), it seems that these two values can be used equally well as assessment of beta-cell function in NIDDM. In conclusion, fasting plasma insulin, fasting plasma C-peptide, and plasma C-peptide 6 min after glucagon stimulation showed a similar and acceptable degree of reproducibility. Plasma insulin 6 min after glucagon and increments in plasma insulin and C-peptide, as well as urinary C-peptide, seem to be less reproducible.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315512     DOI: 10.2337/diacare.10.5.558

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  7 in total

1.  Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control.

Authors:  Maria Anita Radtke; Ingrid Nermoen; Magnus Kollind; Svein Skeie; Jan Inge Sørheim; Johan Svartberg; Ingrid Hals; Torolf Moen; Gry Høst Dørflinger; Valdemar Grill
Journal:  Diabetes Care       Date:  2009-12-22       Impact factor: 19.112

2.  Acute insulin response to intravenous glucose, glucagon and arginine in some subjects at risk for type 1 (insulin-dependent) diabetes mellitus.

Authors:  S Bardet; V Rohmer; D Maugendre; M Marre; G Semana; J M Limal; H Allannic; B Charbonnel; P Saï
Journal:  Diabetologia       Date:  1991-09       Impact factor: 10.122

3.  Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients.

Authors:  E Vandemeulebroucke; B Keymeulen; K Decochez; I Weets; C De Block; F Féry; U Van de Velde; I Vermeulen; P De Pauw; C Mathieu; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2009-11-07       Impact factor: 10.122

4.  Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes.

Authors:  Shogo Funakoshi; Shimpei Fujimoto; Akihiro Hamasaki; Hideya Fujiwara; Yoshihito Fujita; Kaori Ikeda; Shiho Takahara; Kazuaki Nagashima; Masaya Hosokawa; Yutaka Seino; Nobuya Inagaki
Journal:  J Diabetes Investig       Date:  2011-08-02       Impact factor: 4.232

5.  Analysis of factors influencing postprandial C-peptide levels in Japanese patients with type 2 diabetes: Comparison with C-peptide levels after glucagon load.

Authors:  Shogo Funakoshi; Shimpei Fujimoto; Akihiro Hamasaki; Hideya Fujiwara; Yoshihito Fujita; Kaori Ikeda; Shiho Takahara; Yutaka Seino; Nobuya Inagaki
Journal:  J Diabetes Investig       Date:  2011-11-30       Impact factor: 4.232

6.  Postprandial C-peptide to glucose ratio as a predictor of β-cell function and its usefulness for staged management of type 2 diabetes.

Authors:  Eun Young Lee; Sena Hwang; Seo Hee Lee; Yong-Ho Lee; A Ra Choi; Youngki Lee; Byung-Wan Lee; Eun Seok Kang; Chul Woo Ahn; Bong Soo Cha; Hyun Chul Lee
Journal:  J Diabetes Investig       Date:  2014-02-12       Impact factor: 4.232

7.  Minimal functional β-cell mass in intraportal implants that reduces glycemic variability in type 1 diabetic recipients.

Authors:  Pieter Gillard; Robert Hilbrands; Ursule Van de Velde; Zhidong Ling; Da Hae Lee; Ilse Weets; Frans Gorus; Christophe De Block; Leonard Kaufman; Chantal Mathieu; Daniel Pipeleers; Bart Keymeulen
Journal:  Diabetes Care       Date:  2013-09-16       Impact factor: 19.112

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.